28451446|t|Stem cell registry programme for patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting: what benefits does it derive?
28451446|a|Standardization of stem cell therapy requires application of appropriate methods to evaluate safety and efficac y, including long-term pharmacovigilance. To accomplish this objective, a long-term registry programme was installed. We analysed 150 patients with ischemic cardiomyopathy, who received intramyocardial CD133+ bone marrow mononuclear stem cell treatment combined with coronary artery bypass grafting (CABG) or CABG alone. The mortality rate, major adverse cerebral and cardiac events, and functional outcome parameters were evaluated for the time period up to 14 years follow-up. As a result, we have stratified the patient population (96 patients) into responders and non-responders. Furthermore, the analysis of relevant predictors of good response to CD133+ bone marrow mononuclear stem cell treatment was performed. Several positive tendencies related to stem cells transplantation were demonstrated. First, no significant difference in major adverse cardiovascular and cerebral events was observed between stem cell and control group up to 14 years follow-up. Second, an improvement of left ventricle ejection fraction (LVEF) in stem cell group retained for 5 years in contrast with CABG - only group, where no significant changes in LVEF after 2 years were observed. In addition, LVEF under 30% and left ventricle end diastolic diameter above 60 mm were independent predictors of functional response to CD133+ cell therapy. Participants with overt heart failure benefit most from CABG combined with intramyocardial injection of CD133+ bone marrow mononuclear cell within the group. An improvement LVEF in stem cell group remained for 5 years in contrast with the CABG - only group. The patients, in whom the improvement of both LVEF and LVED was observed, have benefited by increased life expectancy.
28451446	0	9	Stem cell	T025	C0038250
28451446	10	18	registry	T170	C0920695
28451446	19	28	programme	T169	C3484370
28451446	33	41	patients	T101	C0030705
28451446	47	70	ischemic cardiomyopathy	T047	C0349782
28451446	82	113	coronary artery bypass grafting	T061	C0010055
28451446	120	128	benefits	T081	C0814225
28451446	145	160	Standardization	T062	C0038136
28451446	164	181	stem cell therapy	T061	C0872278
28451446	218	225	methods	T062	C2911685
28451446	229	237	evaluate	T058	C0220825
28451446	238	256	safety and efficac	T058	C0511730
28451446	270	279	long-term	T079	C0443252
28451446	280	297	pharmacovigilance	T062	C3178990
28451446	318	327	objective	T170	C0018017
28451446	331	340	long-term	T079	C0443252
28451446	341	359	registry programme	T073,T170	C0037585
28451446	391	399	patients	T101	C0030705
28451446	405	428	ischemic cardiomyopathy	T047	C0349782
28451446	434	442	received	T080	C1514756
28451446	443	458	intramyocardial	T024	C0027061
28451446	459	499	CD133+ bone marrow mononuclear stem cell	T025	C1511246
28451446	500	509	treatment	T061	C0087111
28451446	510	518	combined	T080	C0205195
28451446	524	555	coronary artery bypass grafting	T061	C0010055
28451446	557	561	CABG	T061	C0010055
28451446	566	570	CABG	T061	C0010055
28451446	571	576	alone	T081	C0205171
28451446	582	596	mortality rate	T081	C0026565
28451446	598	603	major	T080	C0205164
28451446	604	620	adverse cerebral	T033	C0243095
28451446	625	639	cardiac events	T033	C1556247
28451446	680	689	evaluated	T058	C0220825
28451446	698	709	time period	T079	C1948053
28451446	725	734	follow-up	T058	C1522577
28451446	757	767	stratified	T080	C0205363
28451446	772	779	patient	T101	C0030705
28451446	780	790	population	T098	C1257890
28451446	795	803	patients	T101	C0030705
28451446	810	820	responders	T033	C0919876
28451446	825	839	non-responders	T033	C0919875
28451446	858	866	analysis	T062	C0936012
28451446	870	878	relevant	T080	C2347946
28451446	879	889	predictors	T078	C2698872
28451446	893	906	good response	T033	C0184785
28451446	910	950	CD133+ bone marrow mononuclear stem cell	T025	C1511246
28451446	951	960	treatment	T061	C0087111
28451446	965	974	performed	T169	C0884358
28451446	976	983	Several	T081	C0443302
28451446	1015	1041	stem cells transplantation	T061	C1504389
28451446	1068	1082	no significant	T033	C0243095
28451446	1083	1093	difference	T080	C1705242
28451446	1097	1102	major	T080	C0205164
28451446	1103	1125	adverse cardiovascular	T033	C0243095
28451446	1130	1145	cerebral events	T033	C0243095
28451446	1150	1158	observed	T169	C1441672
28451446	1167	1176	stem cell	T025	C0038250
28451446	1181	1194	control group	T096	C0009932
28451446	1210	1219	follow-up	T058	C1522577
28451446	1232	1243	improvement	T077	C2986411
28451446	1247	1279	left ventricle ejection fraction	T201	C0428772
28451446	1281	1285	LVEF	T201	C0428772
28451446	1290	1299	stem cell	T025	C0038250
28451446	1300	1305	group	T078	C0441833
28451446	1306	1314	retained	T169	C0333118
28451446	1330	1338	contrast	T080	C1979874
28451446	1344	1348	CABG	T061	C0010055
28451446	1351	1355	only	T081	C0205171
28451446	1356	1361	group	T078	C0441833
28451446	1395	1399	LVEF	T201	C0428772
28451446	1442	1446	LVEF	T201	C0428772
28451446	1461	1498	left ventricle end diastolic diameter	T060	C0919652
28451446	1528	1538	predictors	T078	C2698872
28451446	1542	1552	functional	T169	C0205245
28451446	1565	1576	CD133+ cell	T025	C0007634
28451446	1577	1584	therapy	T061	C0302189
28451446	1586	1598	Participants	T098	C0679646
28451446	1604	1623	overt heart failure	T047	C0018801
28451446	1624	1631	benefit	T081	C0814225
28451446	1632	1636	most	T081	C0205393
28451446	1642	1646	CABG	T061	C0010055
28451446	1647	1655	combined	T080	C0205195
28451446	1661	1676	intramyocardial	T024	C0027061
28451446	1677	1686	injection	T061	C1533685
28451446	1690	1725	CD133+ bone marrow mononuclear cell	T025	C1511246
28451446	1737	1742	group	T078	C0441833
28451446	1747	1758	improvement	T077	C2986411
28451446	1759	1763	LVEF	T201	C0428772
28451446	1767	1776	stem cell	T025	C0038250
28451446	1777	1782	group	T078	C0441833
28451446	1807	1815	contrast	T080	C1979874
28451446	1825	1829	CABG	T061	C0010055
28451446	1832	1836	only	T081	C0205171
28451446	1837	1842	group	T078	C0441833
28451446	1848	1856	patients	T101	C0030705
28451446	1870	1881	improvement	T077	C2986411
28451446	1890	1894	LVEF	T201	C0428772
28451446	1899	1903	LVED	T060	C0919652
28451446	1908	1916	observed	T169	C1441672
28451446	1936	1945	increased	T081	C0205217
28451446	1946	1961	life expectancy	T102	C0023671